467 results on '"Vitry, Agnes"'
Search Results
2. OP159 Quality Of Evidence For Clinical Benefit Of Cancer Medicines Assessed For Funding In Australia
3. Flawed evidence underpins approval of new cancer drugs
4. Patterns of comorbidities in women with breast cancer : a Canadian population-based study
5. “Drugs to avoid” to improve quality use of medicines: how is Australia faring?
6. Medication-related quality of care in residential aged care : an Australian experience
7. Pharmaceutical Industry Funding of Health Consumer Groups in Australia : A Cross-sectional Analysis
8. Pharmaceutical Policy in Vietnam
9. Changes in the prevalence of comorbidity in the Australian population with cancer, 2007–2014
10. Medicines access programs to cancer medicines in Australia and New Zealand: An exploratory study
11. Development of comorbidities in men with prostate cancer treated with androgen deprivation therapy: an Australian population-based cohort study
12. Availability, Price, and Affordability of Selected Essential Medicines for Chronic Diseases in 11 Countries of the Asia Pacific Region : A Secondary Analysis
13. Variations in colorectal cancer pattern of care by age and comorbidity in South Australia
14. Associations of advanced age with comorbidity, stage and primary subsite as contributors to mortality from colorectal cancer
15. Pharmaceutical Pricing Policies in Australia
16. Large Language Models and Their Ability for Health Disinformation Generation: Assessing the Adequacy of Current Safeguards and Risk Mitigation Measures
17. Australia to lose agency dedicated to better quality medicine use
18. Cancer drugs in 16 European countries, Australia, and New Zealand: a cross-country price comparison study
19. Doctors' views on the quality of claims provided by pharmaceutical representatives: A comparative study in Malaysia and Australia
20. Access to High-Cost Medicines in Australia
21. Contributors
22. Managed entry agreements for pharmaceuticals in Australia
23. Comorbidity, physical and mental health among cancer patients and survivors: An Australian population‐based study
24. Changes to the Australian Pharmaceutical Benefit Scheme restrictions for biological disease‐modifying antirheumatic drugs have influenced the use of leflunomide
25. Analgesic Use and Daytime Sleepiness in Residents With and Without Dementia in Residential Aged Care Facilities
26. Evaluating medication-related quality of care in residential aged care: a systematic review
27. Chronic disease management: Does the disease affect likelihood of care planning?
28. Occurrence of Comorbidity with Colorectal Cancer and Variations by Age and Stage at Diagnosis
29. ‘Food for Thought’—The Relationship between Diet and Cognition in Breast and Colorectal Cancer Survivors: A Feasibility Study
30. Charlson and Rx-Risk comorbidity indices were predictive of mortality in the Australian health care setting
31. The association between co-morbidity and the use of antidiabetics or adjunctive cardiovascular medicines in Australian veterans with diabetes
32. IS AUSTRALIA'S NATIONAL MEDICINES POLICY FAILING? THE CASE OF COX-2 INHIBITORS
33. ‘Drugs to avoid’: can we improve prescribing appropriateness?
34. Evaluating changes in student health, wellbeing and social circumstances before and during COVID-19 pandemic restrictions in Australia
35. Pharmaceutical Pricing Policies in Australia
36. Comorbidity in the elderly with diabetes: Identification of areas of potential treatment conflicts
37. Approval, reimbursement and pricing of high-cost cancer medicines in Australia
38. Treating Dysentery with Metronidazole in Pakistan
39. Co-Morbidity and Potential Treatment Conflicts in Elderly Heart Failure Patients: A Retrospective, Cross-Sectional Study of Administrative Claims Data
40. Comorbidity of chronic disease and potential treatment conflicts in older people dispensed antidepressants
41. The imperative of happiness for women living with breast cancer
42. Provision of medicines information in Australian community pharmacies
43. Comorbid diabetes and COPD: impact of corticosteroid use on diabetes complications
44. Validity of medication-based co-morbidity indices in the Australian elderly population
45. Inclusion of Older People Reflective of Real‐World Clinical Practice in Cardiovascular Drug Trials
46. Does antidepressant medication use affect persistence with diabetes medicines?
47. Health Consumer Groups and the Pharmaceutical Industry: Is Transparency the Answer?
48. Major bleeding risk associated with warfarin and co-medications in the elderly population
49. Ageing well: Improving the management of patients with multiple chronic health problems
50. Multimorbidity, care complexity and prescribing for the elderly
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.